SCHEMBL7464785

SCHEMBL7464785

Clc1ccc(CCCCCCCCBr)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.53
IGF1R P08069 1/20 0.52
ALOX15 P16050 1/20 0.52
TAAR1 Q96RJ0 2/20 0.48
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47
HDAC5 Q9UQL6 1/20 0.47
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7217191 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL7614753 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL8071211 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL5596095 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL7562067 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL11460578 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL7562217 1.00 KCNH2 (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL1008937 0.98 IGF1R (0.53) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL81407 0.91 TAAR1 (0.52) KCNH2IGF1RALOX15TAAR1HDAC3
SCHEMBL8467011 0.89 KCNH2 (0.45) KCNH2IGF1RALOX15TAAR1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed
EP-1175409-A1 PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2002-01-30 EP disclosed
WO-2000068208-A1 PYRIMIDINONES DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2000-11-16 WO disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
US-6063940-A Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-05-16 US disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed
US-5637736-A Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-06-10 US disclosed
US-5428065-A Treating central nervous system disorders LILLY INDUSTRIES LIMITED (GB) 1995-06-27 US disclosed
EP-0645370-A1 Substituted m-xylylene diamines for the treatment of diseases of the central nervous system LILLY INDUSTRIES LIMITED (GB) 1995-03-29 EP disclosed
EP-0637580-A1 Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1995-02-08 EP disclosed